BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 17544554)

  • 41. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
    Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
    Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cherubism: a systematic literature review of clinical and molecular aspects.
    Chrcanovic BR; Guimarães LM; Gomes CC; Gomez RS
    Int J Oral Maxillofac Surg; 2021 Jan; 50(1):43-53. PubMed ID: 32620450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cherubism].
    Brix M; Peters H; Lebeau J
    Rev Stomatol Chir Maxillofac; 2009 Nov; 110(5):293-8. PubMed ID: 19836038
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Jawing about TNF: new hope for cherubism.
    Novack DV; Faccio R
    Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
    Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
    Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cherubism: best clinical practice.
    Papadaki ME; Lietman SA; Levine MA; Olsen BR; Kaban LB; Reichenberger EJ
    Orphanet J Rare Dis; 2012 May; 7 Suppl 1(Suppl 1):S6. PubMed ID: 22640403
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
    Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Expression of c-Src and comparison of cytologic features in cherubism, central giant cell granuloma and giant cell tumors.
    Wang C; Song Y; Peng B; Fan M; Li J; Zhu S; Bian Z
    Oncol Rep; 2006 Mar; 15(3):589-94. PubMed ID: 16465417
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
    Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
    J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cherubism: a case report.
    Dincă O; Severin E; Vlădan C; Bodnar DC; Bucur A
    Rom J Morphol Embryol; 2014; 55(2 Suppl):655-8. PubMed ID: 25178340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of giant cell tumour of bone cells for Noonan syndrome/cherubism-related mutations.
    Moskovszky L; Idowu B; Taylor R; Mertens F; Athanasou N; Flanagan A
    J Oral Pathol Med; 2013 Jan; 42(1):95-8. PubMed ID: 22725657
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
    Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
    Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathologic study of 24 cases of cherubism.
    Meng XM; Yu SF; Yu GY
    Int J Oral Maxillofac Surg; 2005 Jun; 34(4):350-6. PubMed ID: 16053841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Cherubism: regression of the lesions and spontaneous bone regeneration].
    Timosca GC
    Rev Stomatol Chir Maxillofac; 1996; 97(3):172-7. PubMed ID: 8711332
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multilocular radiolucencies.
    Katz JO; Underhill TE
    Dent Clin North Am; 1994 Jan; 38(1):63-81. PubMed ID: 8307237
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microbe-Dependent Exacerbated Alveolar Bone Destruction in Heterozygous Cherubism Mice.
    Kittaka M; Yoshimoto T; Schlosser C; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
    JBMR Plus; 2020 Jun; 4(6):e10352. PubMed ID: 32537546
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bone dynamics and inflammation: lessons from rare diseases.
    Matsumoto Y; Rottapel R
    Immunol Med; 2020 Jun; 43(2):61-64. PubMed ID: 31999934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cherubism misdiagnosed as giant cell tumor: a case report and review of literature.
    Jiao Y; Zhou M; Yang Y; Zhou J; Duan X
    Int J Clin Exp Med; 2015; 8(3):4656-63. PubMed ID: 26064398
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cherubism: diagnosis, treatment, and comparison with central giant cell granulomas and giant cell tumors.
    Kaugars GE; Niamtu J; Svirsky JA
    Oral Surg Oral Med Oral Pathol; 1992 Mar; 73(3):369-74. PubMed ID: 1545971
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Cherubism: pathology and diagnosis. Analysis of 7 cases].
    Dominguez FV; Keszler A
    Rev Asoc Odontol Argent; 1984 Aug; 72(5):136-8, 140, 142-5. PubMed ID: 6599133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.